Cover Image
市場調查報告書

B細胞慢性淋巴細胞白血病:開發平台分析

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 253678
出版日期 內容資訊 英文 174 Pages
訂單完成後即時交付
價格
Back to Top
B細胞慢性淋巴細胞白血病:開發平台分析 B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 174 Pages
簡介

B細胞慢性淋巴性白血病是最常見的白血病,會影響B細胞株的淋巴球。雖然致病因素尚不明,但一般認為是由於抑制血液細胞增殖的基因有1∼2個部位受損所造成。此外,家族病史也是提升發病風險的要素。由於惡化速度遲緩,許多人未能發現病徵,而是藉由定期血液檢查才發現。治療藥有錠劑型及點滴等。

本報告提供全球各國的B細胞慢性淋巴性白血病(B-CLL)治療法的開發中產品開發情形相關分析,提供開發中產品的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 調查範圍

B細胞慢性淋巴細胞白血病概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • AB Science SA
  • Amgen Inc.
  • Celgene Corporation
  • Dynavax Technologies Corporation
  • Eisai
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd.
  • iDD biotech SAS
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Molecular Templates Inc.
  • Noxxon Pharma AG
  • 小野藥品工業
  • Regeneron Pharmaceuticals, Inc.
  • TheraMAB LLC
  • Unum Therapeutics, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 202-b
  • AB-8779
  • alemtuzumab biosimilar
  • AMG-319
  • ATTCK-20
  • Cellular Immunotherapy for Hematological Malignancies
  • Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia
  • Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia
  • Cellular Immunotherapy to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Target CD19 for Cancer
  • Cellular Immunotherapy to Target CD19 for Oncology
  • E-7449
  • IDD-001
  • IDD-002
  • JNJ-64052781
  • lenalidomide
  • MAT-303
  • MT-3724
  • olaptesed pegol
  • ONO-4059
  • REGN-1979
  • SD-101
  • TAB-08
  • tocilizumab

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9652IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2017, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 12, 7, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.

B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • B-Cell Chronic Lymphocytic Leukemia - Overview
    • B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
    • AB Science SA
    • Aduro BioTech Inc
    • BioInvent International AB
    • Boehringer Ingelheim GmbH
    • Celgene Corp
    • Cell Source Inc
    • Cellectis SA
    • Dynavax Technologies Corp
    • Elsalys Biotech SAS
    • F. Hoffmann-La Roche Ltd
    • iDD biotech SAS
    • Immunomedics Inc
    • Johnson & Johnson
    • Juno Therapeutics Inc
    • Lymphocyte Activation Technologies SA
    • Mabion SA
    • MedImmune LLC
    • MEI Pharma Inc
    • Millennium Pharmaceuticals Inc
    • Molecular Templates Inc
    • Novartis AG
    • Noxxon Pharma AG
    • Ono Pharmaceutical Co Ltd
    • Portola Pharmaceuticals Inc
    • Regeneron Pharmaceuticals Inc
    • Sunesis Pharmaceuticals Inc
    • TheraMAB LLC
    • Unum Therapeutics Inc
  • B-Cell Chronic Lymphocytic Leukemia - Drug Profiles
    • 202-b - Drug Profile
    • 2X-121 - Drug Profile
    • AB-8779 - Drug Profile
    • alemtuzumab biosimilar - Drug Profile
    • alisertib - Drug Profile
    • BI-1206 - Drug Profile
    • BI-836826 - Drug Profile
    • BION-1301 - Drug Profile
    • Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile
    • Cellular Immunotherapy for Hematological Malignancies - Drug Profile
    • Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
    • Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile
    • Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile
    • Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile
    • Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile
    • Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
    • cerdulatinib - Drug Profile
    • DTRMWXHS-12 - Drug Profile
    • durvalumab - Drug Profile
    • duvortuxizumab - Drug Profile
    • ELB-021 - Drug Profile
    • IDD-001 - Drug Profile
    • IDD-002 - Drug Profile
    • lenalidomide - Drug Profile
    • ME-401 - Drug Profile
    • mRNA ACTR + rituximab - Drug Profile
    • MT-3724 - Drug Profile
    • olaptesed pegol - Drug Profile
    • REGN-1979 - Drug Profile
    • rituximab biosimilar - Drug Profile
    • SD-101 - Drug Profile
    • SNS-062 - Drug Profile
    • TAB-08 - Drug Profile
    • tirabrutinib - Drug Profile
    • tisagenlecleucel-T - Drug Profile
    • tocilizumab - Drug Profile
    • UCART-22 - Drug Profile
    • UCARTCS-1 - Drug Profile
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects
  • B-Cell Chronic Lymphocytic Leukemia - Discontinued Products
  • B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioInvent International AB, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corp, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cellectis SA, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corp, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies SA, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Mabion SA, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by MedImmune LLC, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Novartis AG, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Portola Pharmaceuticals Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics Inc, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top